首页> 外文期刊>The Journal of Nuclear Medicine >Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors
【24h】

Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors

机译:177Lu-DOTATATE肽受体放射性核素治疗后持续的血液功能障碍:胃肠道胰腺神经内分泌肿瘤患者的发病率,病程和预测因素

获取原文
       

摘要

Peptide receptor radionuclide therapy (PRRT) may induce long-term toxicity to the bone marrow (BM). The aim of this study was to analyze persistent hematologic dysfunction (PHD) after PRRT with 177Lu-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs). Methods: The incidence and course of PHD were analyzed in 274 GEP NET patients from a group of 367 patients with somatostatin receptor–positive tumors. PHD was defined as diagnosis of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN), MDS/MPN, or otherwise unexplained cytopenia (for 6 mo). Using data from The Netherlands Cancer Registry, the expected number of hematopoietic neoplasms (MDS, AML, MPN, and MDS/MPN) was calculated and adjusted for sex, age, and follow-up period. The following risk factors were assessed: sex, age over 70 y, bone metastasis, prior chemotherapy, prior external-beam radiotherapy, uptake on the [111In-DTPA0]octreotide scan, tumor load, grade 3–4 hematologic toxicity during treatment, estimated absorbed BM dose, elevated plasma chromogranin A level, baseline blood counts, and renal function. Results: Eleven (4%) of the 274 patients had PHD after treatment with 177Lu-DOTATATE: 8 patients (2.9%) developed a hematopoietic neoplasm (4 MDS, 1 AML, 1 MPN, and 2 MDS/MPN) and 3 patients (1.1%) developed BM failure characterized by cytopenia and BM aplasia. The median latency period at diagnosis (or first suspicion of a PHD) was 41 mo (range, 15–84 mo). The expected number of hematopoietic neoplasms based on The Netherlands Cancer Registry data was 3.0, resulting in a relative risk of 2.7 (95% confidence interval, 0.7–10.0). No risk factors for PHD could be identified for the GEP NET patients, not even bone metastasis or estimated BM dose. Seven patients with PHD developed anemia in combination with a rise in mean corpuscular volume. Conclusion: The prevalence of PHD after PRRT with 177Lu-DOTATATE was 4% in our patient population. The median time at which PHD developed was 41 mo after the first PRRT cycle. The relative risk for developing a hematopoietic neoplasm was 2.7. No risk factors were found for the development of PHD in GEP NET patients.
机译:肽受体放射性核素治疗(PRRT)可能诱导对骨髓(BM)的长期毒性。这项研究的目的是分析胃肠道胰腺神经内分泌肿瘤(GEP NETs)患者接受177Lu-DOTATATE进行PRRT后的持续血液功能障碍(PHD)。方法:分析了367名生长抑素受体阳性肿瘤患者中的274名GEP NET患者的PHD发生率和病程。 PHD被定义为诊断为骨髓增生异常综合症(MDS),急性髓性白血病(AML),骨髓增生性肿瘤(MPN),MDS / MPN或其他原因不明的血细胞减少(> 6 mo)。使用荷兰癌症登记处的数据,计算出预期的造血肿瘤数量(MDS,AML,MPN和MDS / MPN),并针对性别,年龄和随访时间进行了调整。评估了以下风险因素:性别,70岁以上的年龄,骨转移,先前的化学疗法,先前的体外放射疗法,[111In-DTPA0]奥曲肽扫描的摄取,肿瘤负荷,治疗期间3-4级血液学毒性吸收的BM剂量,血浆嗜铬粒蛋白A水平升高,基线血球计数和肾功能。结果:274例患者接受177Lu-DOTATATE治疗后发生PHD,其中11例(4%):8例(2.9%)出现了造血性肿瘤(4 MDS,1 AML,1 MPN和2 MDS / MPN)和3例( 1.1%)发展为以血细胞减少和BM发育不全为特征的BM衰竭。诊断时的中位潜伏期(或首次怀疑是PHD)为41 mo(范围15-84 mo)。根据荷兰癌症登记处的数据,预期的造血肿瘤数量为3.0,相对危险度为2.7(95%置信区间为0.7-10.0)。对于GEP NET患者,没有发现PHD的危险因素,甚至没有骨转移或估计的BM剂量。七名PHD患者发生贫血并伴有平均红细胞体积增加。结论:在我们的患者人群中,PRRT与177Lu-DOTATATE联合使用后,PHD的患病率为4%。在第一个PRRT周期后,PHD发生的中位时间为41 mo。发生造血肿瘤的相对风险为2.7。在GEP NET患者中未发现PHD发展的危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号